Clinical trials
Hematologic Diseases trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
61 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 3 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Unknown status | 14 |
| Recruiting | 12 |
| Active, not recruiting | 6 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nanfang Hospital, Southern Medical University | 7 |
| Loxo Oncology, Inc. | 5 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| He Huang | 3 |
| The First Affiliated Hospital of Soochow University | 3 |
| Abbott Medical Devices | 2 |
| Anhui Provincial Hospital | 2 |
| Genzyme, a Sanofi Company | 2 |
| Peking University People's Hospital | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 61 |
| Neoplasms | 9 |
| Hematologic Neoplasms | 7 |
| Anemia | 6 |
| Hemorrhagic Disorders | 6 |
| Immune System Diseases | 6 |
| Lymphoma, B-Cell | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Thrombocytopenia | 5 |
| Anemia, Hemolytic | 4 |
Trials
Showing 51 to 61 of 61. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.